Summary of Key Points Core Viewpoint - The A-share IPO market is active with three companies approved for listing, while the Hong Kong IPO market continues to thrive, particularly in the innovative drug and high-end manufacturing sectors, with several key players making significant moves [2][6]. Group 1: A-share IPO Approvals - Three companies received approval for IPOs this week: Guangdong Huahui Intelligent Equipment Co., Ltd., Anhui Xinfeng New Energy Technology Co., Ltd., and Shandong Chunguang Technology Group Co., Ltd. [2][3][4]. - Huahui Intelligent focuses on high-end intelligent equipment and has seen rapid revenue growth, projecting over 4.2 billion yuan in revenue for 2024 and over 620 million yuan in net profit [3]. - Xinfeng Technology specializes in thermal management components for electric vehicles, with projected revenues of 6 billion yuan in 2024 and 13.81 billion yuan in 2025 [4][5]. - Chunguang Group leads in the production of soft magnetic ferrite powder, with revenues of 10.15 billion yuan in 2022 and a planned fundraising of 7.51 billion yuan for its IPO [5]. Group 2: Hong Kong IPO Market Activity - The Hong Kong IPO market welcomed five new listings, including four companies and one on the Sci-Tech Innovation Board, covering diverse sectors such as chemical new materials and cardiovascular medical devices [6][7]. - Guoen Technology debuted on the Hong Kong Stock Exchange, raising approximately 1 billion HKD, with plans for expansion in Thailand and domestic production [6]. - Beixin Life, the first medical device company listed on the Sci-Tech Innovation Board, saw its stock price surge by 183.33% on its first day, focusing on cardiovascular intervention devices [7]. - Leading companies in the PCB equipment sector, such as Dazhu CNC, raised significant funds for expansion into Southeast Asia, while Zhuozheng Medical and Muyuan Foods had mixed performances post-listing [8]. Group 3: Upcoming IPOs and Market Trends - The Hong Kong IPO market continues to be driven by hard technology, with companies like Danuo Pharmaceutical and Xian Dao Intelligent preparing for their listings, focusing on innovative drugs and lithium battery equipment [9][10]. - Danuo Pharmaceutical is set to raise funds for global clinical advancements, with its core product showing promising clinical data [9]. - Xian Dao Intelligent aims to raise 41.66 billion HKD, with a significant projected profit increase of 424% by 2025, expanding its services beyond lithium battery equipment [10]. - Wolong Nuclear Materials is also preparing for an IPO, focusing on new materials and global capacity expansion, with a fundraising target of up to 27.34 billion HKD [11].

在此基础上，丹诺医药形成了坚实的技术护城河。截至2026年1月24日，公司拥有42项已授权专利及87项专利申请， 为核心产品提供了有效的知识产权保护。 在全球抗菌药物耐药性（AMR）危机日趋严峻、肠道菌群代谢与疾病关系日益明确的背景下，丹诺医药迈入资本视 野。 作为一家临近商业化阶段的生物科技公司，丹诺医药专注于发现、开发及商业化针对细菌感染及细菌代谢相关疾病的 差异化创新药产品。其核心产品利福特尼唑有望成为自幽门螺杆菌发现以来全球首款针对幽门螺杆菌感染的新分子实 体药物，并在尚处蓝海的核心适应症中抢占先发优势。 一、构筑技术平台与产品管线的双重壁垒 丹诺医药依托以自主开发的多靶点偶联分子技术进行新药研发，聚焦细菌感染和细菌代谢相关疾病领域。 1、全球领先的多靶点偶联分子技术平台 丹诺医药的核心竞争力源于其全球领先的多靶点偶联分子技术平台以及由此构建的差异化产品管线。 该技术平台是全面整合的研发引擎，涵盖药物设计、合成及评估全流程，战略聚焦于细菌感染及细菌代谢相关疾病领 域。通过该平台，公司根据适应症选择合适的靶点进行偶联分子的设计与合成，并利用其独特的评价体系进行偶联分 子的优化。 这一技术显著降低与安全性 ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 TenNor Therapeutics (Suzhou) Limited 丹諾醫藥（蘇州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》送呈香港公司註冊處處長登記 前，本公司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約或邀請， 有意投資者務請僅依據送呈香港公司註冊處處長登記的本公司招股章程作出投資決定；有關文本將 於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本 文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、其保薦人、整體協 調人、顧問或包銷團成員在香港或任何其他司法權區必須進行發售活動的責任。本公司最終 會否進行發售仍屬未知之數； (c) 本文件或其任何補充、修訂或更換附頁的內 ...

Core Insights - The article discusses the breakthrough in the treatment of Helicobacter pylori (H. pylori) infections, highlighting a new triple therapy regimen containing rifaximin that shows higher eradication success rates and lower adverse reaction rates compared to the commonly used bismuth quadruple therapy [4][8]. Group 1: Treatment Efficacy - A phase III clinical trial involving 700 initial treatment patients for H. pylori infection demonstrated that the rifaximin-based triple therapy is more effective than the standard bismuth quadruple therapy [4][8]. - The new treatment regimen is noted for requiring fewer medications and being more convenient for patients [4]. Group 2: Safety Profile - The safety data from the trial indicated that treatment-related adverse events (TEAEs) occurred in 36.4% of patients, with severe TEAEs (grade 3 or higher) being rare, affecting only 0.9% of participants [7]. - The study reported a total of 315 TEAEs, with 45.2% of patients experiencing any TEAE [7]. Group 3: Drug Development - Rifaximin is a novel drug developed in China specifically targeting H. pylori infections, showing broad sensitivity and overcoming high resistance issues commonly associated with H. pylori [8]. - The introduction of this drug is expected to have significant clinical and social implications, garnering attention from both domestic and international academic circles [8].

Core Viewpoint - Danuo Pharmaceutical, a biotech company based in Suzhou, is on the verge of submitting a new drug application for the world's first and only new molecular entity candidate for treating Helicobacter pylori infection, marking a significant milestone in the field of antibiotic development [5][10][14]. Company Overview - Founded in 2013 by Ma Zhenkun, Danuo Pharmaceutical focuses on developing treatments for bacterial infections and related diseases, with a strong emphasis on Helicobacter pylori [8][9]. - The company has a pipeline of seven drugs in development, including "Rifotnizole," which has successfully completed Phase III clinical trials [10][13]. Investment and Financials - Danuo Pharmaceutical has successfully raised funds through multiple financing rounds, reaching a valuation of over 2 billion yuan after its E round [15][17]. - The company has accumulated a net loss of 192 million yuan in 2023, which decreased to 146 million yuan in 2024, indicating a positive trend in financial performance [14]. Market Potential - The global market for antibacterial drugs is projected to grow from $45.5 billion in 2024 to $60.3 billion by 2029, with the market for Helicobacter pylori treatments expected to increase from $6.9 billion to $10 billion in the same period [14]. Strategic Partnerships - Danuo has established a commercial partnership with Yuan Da Life Science Group for the marketing and distribution of "Rifotnizole," which includes a payment agreement potentially worth up to 775 million yuan [14][17]. Future Outlook - The company plans to submit the new drug application for "Rifotnizole" by the end of August 2025 and aims to establish a drug production and R&D base in Zhongshan, Guangdong [17][18].

Core Viewpoint - Danuo Pharmaceutical (Suzhou) Co., Ltd. is seeking to go public on the Hong Kong Stock Exchange, highlighting its innovative drug development in the field of bacterial infections, particularly targeting Helicobacter pylori infections, despite facing significant financial challenges [2][3]. Company Overview - Founded in 2013, Danuo Pharmaceutical has completed seven rounds of financing, with a post-investment valuation of 2.013 billion RMB in its latest round [2]. - The company’s core product, Rifoternizole, is positioned to be the first new molecular entity approved for treating Helicobacter pylori infections globally [3][4]. Product Pipeline - Danuo has developed a differentiated pipeline consisting of seven innovative assets, including three core products: Rifoternizole (TNP-2198), Rifocquinone (TNP-2092) injection, and TNP-2092 oral formulation [3]. - Rifoternizole is the most advanced product, with plans to submit a new drug application to the National Medical Products Administration by August 2025 [3]. Financial Situation - The company reported a cumulative loss of 376 million RMB in 2023, with a net debt of 932 million RMB and cash reserves of only 146 million RMB as of March 2025 [6][8]. - Research and development expenses accounted for a significant portion of the losses, with 90.7%, 82%, and 65.3% of total R&D spending allocated to core product development during the reporting period [6]. Market Potential - The global market for antibacterial drugs is projected to grow from 45.5 billion USD in 2024 to 84.3 billion USD by 2035, indicating a robust industry outlook despite challenges in the Chinese market [9]. Shareholder and Supplier Dynamics - WuXi AppTec, a major shareholder, also serves as a key supplier, raising potential concerns regarding the independence and fairness of related transactions [9][11]. - The largest supplier, identified as Supplier B, accounted for 53.5% of total procurement in the first quarter of 2025, further emphasizing the intertwined relationship between Danuo and WuXi [11][12].

Core Viewpoint - Helicobacter pylori (H. pylori) is a significant public health issue globally, with an infection rate exceeding 50%, and is closely linked to gastric cancer, classified as a Class I carcinogen by the World Health Organization [1][2] Group 1: Market Demand and Growth - The prevalence of H. pylori in China is notably high, with an overall infection rate exceeding 70%, leading to approximately 340,000 new gastric cancer cases annually, accounting for 42% of global cases related to H. pylori [2] - The global market for H. pylori treatment drugs was valued at $5.3 billion in 2019 and is projected to grow at a compound annual growth rate (CAGR) of 6.0%, reaching $6.9 billion by 2024, and further expanding to $10 billion by 2029 [3][4] - The Chinese market for H. pylori treatment drugs was valued at 5.6 billion RMB in 2019, expected to grow to 6.8 billion RMB by 2029, with a CAGR of 4.3% [4] Group 2: Treatment and Innovation - The detection and treatment rates of H. pylori infections in China are expected to rise from 3.0% in 2019 to 3.6% in 2024, and further to 5.8% by 2035 [3] - The American College of Gastroenterology recommends a shift from traditional triple therapy to a quadruple therapy due to rising antibiotic resistance, highlighting the need for innovative treatments [7] - Dano Pharmaceutical's Rifoternizole is the only innovative antibacterial drug currently in development for H. pylori treatment, with plans to submit a New Drug Application (NDA) by August 2025 [7][8] Group 3: Company Overview and Financials - Dano Pharmaceutical, established in 2013, focuses on developing differentiated innovative drug products to address unmet clinical needs in bacterial infections [8] - The company has a pipeline of seven innovative assets, including Rifoternizole, which is designed to overcome antibiotic resistance and improve treatment outcomes [9] - Despite the promising pipeline, Dano Pharmaceutical reported operating losses of approximately 122 million RMB, 77.8 million RMB, and 17.1 million RMB for the years 2023, 2024, and the first three months of 2025, respectively [11][12]

Core Viewpoint - Helicobacter pylori (H. pylori) infection is a significant public health issue globally, with an infection rate exceeding 50%, and is closely linked to gastric cancer, classified as a Group I carcinogen by the World Health Organization [1][2] Industry Overview - H. pylori is associated with various gastric diseases, including gastric ulcers and chronic gastritis, with approximately 80% of gastric cancer cases related to this pathogen [2] - In China, H. pylori infection rates are notably high, with an overall infection rate exceeding 70%, leading to an estimated 340,000 new gastric cancer cases annually, accounting for 42% of global cases related to H. pylori [2] - The global market for H. pylori treatment drugs was valued at $5.3 billion in 2019 and is projected to grow at a compound annual growth rate (CAGR) of 6.0%, reaching $6.9 billion by 2024 and $10 billion by 2029 [3][4] Company Overview - Dano Pharmaceutical (Suzhou) Co., Ltd. is a biotechnology company focused on developing innovative drugs for bacterial infections, with its core product, Rifoternizole (TNP-2198), being the only innovative antibacterial drug in development for H. pylori infection [8][11] - The company has established a differentiated pipeline with seven innovative assets, including TNP-2198, which aims to overcome antibiotic resistance and improve treatment outcomes [9][10] - Dano Pharmaceutical plans to submit a New Drug Application (NDA) for TNP-2198 by the end of August 2025, following successful Phase III clinical trials demonstrating its advantages over existing treatments [10][11] Market Potential - The Chinese market for H. pylori treatment drugs is expected to grow from 5.6 billion RMB in 2019 to 6.8 billion RMB by 2029, with a CAGR of 4.3% [4] - The introduction of TNP-2198 is anticipated to significantly impact the H. pylori treatment market, especially given the rising antibiotic resistance and the shift towards more effective treatment regimens [7][11] Financial Considerations - Dano Pharmaceutical has reported operating losses of approximately 122 million RMB, 77.8 million RMB, and 17.1 million RMB for the years 2023, 2024, and the first three months of 2025, respectively [12] - The company is actively seeking to raise funds through an IPO to support its ongoing research and development efforts, which require substantial financial resources [12][13]

Core Viewpoint - Danuo Pharmaceutical (Suzhou) Co., Ltd. is seeking to go public on the Hong Kong Stock Exchange, focusing on unmet clinical needs in the antibacterial drug sector, particularly targeting Helicobacter pylori infections [1][2]. Company Overview - Danuo Pharmaceutical specializes in the antibacterial drug field, addressing bacterial infections and related diseases [2]. - The company was founded in October 2012 and has undergone several rounds of financing, with a post-money valuation of approximately 2.013 billion RMB after the latest round [2][3]. - The company is managed by Dr. Ma Zhenkun, who has over 30 years of experience in infectious disease drug development [4][5]. Product Pipeline - Danuo has seven drug candidates in development, including three core products: 1. Rifoterinazole (TNP-2198), the first new molecular entity for treating Helicobacter pylori infections [9][11]. 2. Rifoketone (TNP-2092) injection, a potential first-in-class drug for implant-related bacterial infections [13]. 3. TNP-2092 oral formulation, aimed at treating gut microbiota-related metabolic diseases [14]. Market Opportunity - The global market for antibacterial drugs is projected to grow from $45.5 billion in 2024 to $60.3 billion by 2029, with a further increase to $84.3 billion by 2035 [8]. - In China, the antibacterial drug market is expected to decline slightly from 122.9 billion RMB in 2024 to 102.6 billion RMB by 2035 due to volume-based procurement policies [8]. Financial Performance - Danuo Pharmaceutical has not yet generated revenue from product sales, recording net losses of 192 million RMB in 2023 and 146 million RMB in 2024 [16][17]. - The company’s research and development expenses are a significant part of its cost structure, with R&D costs of 108 million RMB in 2023 [18]. Future Prospects - The company plans to submit a new drug application for Rifoterinazole by the end of August 2025, which is crucial for its future revenue generation [12][18].

Core Viewpoint - Danuo Pharmaceutical (Suzhou) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, focusing on the unmet clinical needs in the field of antibacterial drugs, particularly targeting Helicobacter pylori infections [1][2]. Company Overview - Danuo Pharmaceutical specializes in antibacterial drugs, addressing bacterial infections and related diseases. The company was founded in 2012 and has undergone several rounds of financing, with a post-financing valuation of 2.013 billion RMB as of July 25, 2025 [2][3]. - The company is managed by Dr. Ma Zhenkun, who has over 30 years of experience in infectious disease drug development [4][5]. Product Pipeline - Danuo has seven research pipelines, including three core products: 1. Rifoternizole (TNP-2198), the first and only new molecular entity candidate for treating Helicobacter pylori infections [10]. 2. Rifoqinone (TNP-2092) injection, a potential first-in-class drug for treating implant-associated bacterial infections [13]. 3. TNP-2092 oral formulation, the first multi-target antibacterial candidate for treating gut microbiota-related diseases [15]. Market Opportunity - The global antibacterial drug market is projected to grow from $45.5 billion in 2024 to $60.3 billion by 2029, and further to $84.3 billion by 2035. In China, the market size is expected to decline slightly from 122.9 billion RMB in 2024 to 102.6 billion RMB by 2035 due to volume-based procurement [8]. Financial Performance - Danuo Pharmaceutical has not yet generated revenue from product sales, recording net losses of 192 million RMB in 2023, 146 million RMB in 2024, and 38 million RMB in the first quarter of 2025 [16][17]. - The company's research and development expenses are a significant part of its cost structure, amounting to 108 million RMB in 2023 and 69.8 million RMB in 2024 [19]. Future Prospects - The core product, Rifoternizole, is expected to submit a new drug application by the end of August 2025, indicating a potential pathway to commercialization [12][19].